Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selumetinib and APG-115 in NF1 and MPNST
NCT06735820Phase 2Recruiting
- Start
- Jun 2026
- Primary completion
- Oct 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of selumetinib, alrizomadlin in malignant peripheral nerve sheath tumor (MPNST), neurofibromatosis type 1 (NF1), neurofibroma. Started Jun 2026; status: recruiting.
02
Drugs
selumetinibalrizomadlin
03
Conditions
malignant peripheral nerve sheath tumor (MPNST)neurofibromatosis type 1 (NF1)neurofibroma
Beyond the preview
Go deeper on NCT06735820.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06735820.